Fixed-dose combination antiretroviral therapy administered as a single-tablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.
Blanco, J., Montaner, J., Marconi, V., Santoro, M., Campos Loza, A., Shafer, R., et al. (2014). Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy. AIDS, 28(17), 2531-2539 [10.1097/QAD.0000000000000424].
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy
SANTORO, MARIA;PERNO, CARLO FEDERICO;
2014-11-13
Abstract
Fixed-dose combination antiretroviral therapy administered as a single-tablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2014_Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
505 kB
Formato
Adobe PDF
|
505 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
